Moderna’s mRNA vaccine for RSV has been FDA approved for adults 60 and older, marketed as mResvia. The vaccine is expected to be available before the 2024/2025 respiratory virus season. It is based on prefusion F protein technology, showing 78.7% efficacy in initial studies. Compared to GSK and Pfizer’s RSV vaccines, mResvia is administered via prefilled syringe for convenience. While GSK’s vaccine had some safety concerns, mResvia showed no serious issues. Moderna aims for mResvia to be successful as demand for Covid-19 vaccines declines. Despite competition, analysts see a significant market opportunity for Moderna’s new RSV vaccine.
Source link
FDA Approves Moderna RSV Vaccine, an mRNA Alternative to GSK and Pfizer Products
